- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
M Pharmaceutical Arranges Placement to Settle Debt
M Pharmaceutical Inc. (CSE:MQ) announced has reached agreement with its creditors to settle $743,266.36 of payables in exchange for convertible debenture notes.
M Pharmaceutical Inc. (CSE:MQ) announced has reached agreement with its creditors to settle $743,266.36 of payables in exchange for convertible debenture notes.
As quoted in the press release:
The company debt will be settled by issuing convertible debentures, convertible into common stock at an exercise price of 10 cents. The term of the notes is 36 months at 10-per-cent annual simple interest. The interest shall be paid up front, through the issuance of interest units. Each interest unit consists of one share of the company’s common stock (at a deemed price of five cents per unit) and one warrant with an exercise price of 10 cents and a term of two years. Common stock issued under this placement is subject to a standard four-month lockup period as required by the Canadian Securities Exchange.
M Pharmaceutical CEOÂ Matthew B. Lehman stated:
I am pleased we have reached this settlement with the company’s creditors. This is a significant milestone that restructures the fundamentals of our financial situation. It allows us to develop our Trimeo, Trimtec and eMosquito technologies with a stronger balance sheet.
Connect with M Pharmaceutical Inc. (CSE:MQ) to receive an Investor Kit
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.Â